ClinicalTrials.gg
RecruitingNCT06341205iRITUXUpdated Jun 22, 2026

Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)

A Phase 3 interventional study of RiTUXimab Injection in Membranous Nephropathy, sponsored by Centre Hospitalier Universitaire de Nice. Recruiting at 14 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Centre Hospitalier Universitaire de Nice · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing rituximab in Glomerulonephritis, Membranous — 7 open to participants now, 8 under way, 4 of them phase 3. Rituximab · Glomerulonephritis, Membranous.

Planned enrollment
4th of 15
120 · median 78
Started
2025
with 1 other
Phase 3
5 of 15
2 open now
Registered
13th of 15
by date
Lead sponsor
2 of 15
Centre Hospitalier Universitaire de Nice

Among the 15 studies testing rituximab in Glomerulonephritis, Membranous, this one is the 4th largest by planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 3, and was the 13th registered.

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

Browse Glomerulonephritis, Membranous studies →

Open to participants now

7 of the 15 studies testing rituximab in Glomerulonephritis, Membranous are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 13 (32%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing rituximab in Glomerulonephritis, Membranous, or all of them as a file.
02

Study summary

Membranous nephropathy is an autoimmune disease affecting the kidney, and the most common cause of nephrotic syndrome in non-diabetic Caucasian adults. The course of this disease is highly variable from one individual to another, ranging from spontaneous remission to progressive chronic kidney disease.

The identification of autoantibodies - e.g., the phospholipase A2 receptor type 1 (PLA2R1) - has promoted the use of immunosuppressive drugs such as rituximab which is now a safe and effective first-line treatment for the management of membranous nephropathy. However, up to 40% of patients do not respond to a first course of rituximab treatment. In nephrotic patients, due to urinary drug loss, rituximab blood level is lower than in other autoimmune diseases treated with rituximab without proteinuria. This high urinary drug loss decreases the drug exposure, potentially explaining why rituximab regimen with low dose infusions (375 mg/m2) did not demonstrate efficacy after month-6 compared to a non-immunosuppressive antiproteinuric treatment in a previous study. In contrast, a regimen of two 1-g infusions two weeks apart was associated with a significantly greater remission rate after 6 months.

Recently, the investigators have shown that after two 1-g rituximab infusions, the rituximab blood level 3 months after the first rituximab infusion, was correlated with the likelihood of remission after 6 and 12 months of the rituximab treatment. Patients with positive rituximab blood level 3 months after treatment had a higher chance of remission at month-6 and at month-12 than patients with an undetectable rituximab level at month-3.

Nowadays, machine learning algorithms are increasingly used in medicine, especially in pharmacology, to predict the exposure to a drug, the initial dose to administer or the interval between two infusions.

The objective of this study is to use a machine learning algorithm predicting the risk of having an undetectable residual level of rituximab 3 months after treatment, in order to propose a personalized treatment management with early additional doses of rituximab for the patients at risk.

03

Conditions studied

  • Membranous Nephropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Ongoing episode of membranous nephropathy diagnosed by the presence of anti-PLA2R1 antibodies detected by ELISA (≥ 14 RU/ml, EUROIMMUN): the result must be validated by the Coordination team before randomization.
  • Nephrotic syndrome defined by proteinuria > 3.5 g/24h (or UPCR > 3.5 g/g) and serum albumin \< 30 g/L at diagnosis
  • Estimated (CKD-EPI formula) > 30 mL/min/1,73 m2
  • Indication for rituximab treatment according to the KDIGO and French guidelines
  • Non- antiproteinuric treatment at stable dose for 2 weeks according to French guidelines, including a renin angiotensin aldosterone system inhibitor, a diuretic and a low-salt diet at maximal tolerated dose (i.e., absence of orthostatic hypotension and no increase in creatinine > 30%)

Exclusion criteria

Exclusion Criteria:

  • Secondary Membranous nephropathy related to cancer, infection, systemic lupus, drug
  • Diagnosis of PLA2R1-associated Membranous nephropathy not confirmed by the Coordination team (validation mandatory for randomization)
  • Pregnancy or breastfeeding
  • treatment (including rituximab) in the 6 months preceding inclusion
  • Presence of anti-rituximab antibodies detected by Central Lab
  • Cancer under treatment
  • Patients with active, severe infections
  • to the active substance or
  • Patients severely immunocompromised
  • Severe heart failure or severe, uncontrolled cardiac disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Standard-of-care

    rituximab treatment 1gram x 2 (day-0, day-15)

    Drug: RiTUXimab Injection

  • Experimental
    Personalised treatment

    personalized treatment based on the algorithm for assessing the risk of having undetectable rituximab level after 3 months: * Patients with a risk between 0 and 50% will receive 1gram x2 (day-0, day-15) * Patients with a risk between 51 and 75% will receive 1gram x 3 (day-0, day-15, day-30) * Patients with a risk between 76 and 100% will receive 1gram x 4 (day-0, day-15, day-30, day-45)

    Drug: RiTUXimab Injection

Interventions

  • DrugRituximabStudies of RituximabRituximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dose administered will depend on randomisation and for experimental Arm on the risk of having undetectable rituximab level after 3 months

06

What researchers measure

Primary outcomes

  1. Clinical remission (complete or partial) after 6 months of rituximab initiation

    Clinical remission (complete or partial) according to KDIGO and French guidelines: * Complete: urine protein/creatinine ratio (UPCR) \<0.3 g/g and serum albumin\>30 g/L and Glomerular Filtration Rate (estimated by CKD-EPI formula) \>60 ml/min/1.73m2 * Partial: UPCR \<3.5 g/g with a decrease \>50% from baseline (i.e., at first rituximab infusion) and serum albumin improvement or normalization and stable serum creatinine (or increase \<30%).

    Time frame: 6 months

Secondary outcomes

  1. Complete clinical remission after 12 months of rituximab initiation

    Complete remission: urine protein/creatinine ratio (UPCR) \<0.3 g/g and serum albumin\>30 g/L and Glomerular Filtration Rate (estimated by CKD-EPI formula) \>60 ml/min/1.73m2

    Time frame: 12 months

  2. Partial clinical remission after 12 months of rituximab initiation

    Partial remission: UPCR \<3.5 g/g with a decrease \>50% from baseline (i.e., at first rituximab infusion) and serum albumin improvement or normalization and stable serum creatinine (or increase \<30%).

    Time frame: 12 months

  3. Immunological remission: anti-PLA2R1 depletion

    Immunological remission: anti-PLA2R1 depletion (i.e., PLA2R1 titer \< 14 RU/mL by ELISA method) at month-3, month-6 and month-12

    Time frame: 12 months

  4. Change in urine protein/creatinine ratio (UPCR)

    Percentage of change in urine albumin/creatinine ratio (mg/g) from day-0 to month-3, month-6, month-9, month-12

    Time frame: 12 months

  5. Change in serum creatinine

    Percentage of change in serum creatinine (μmol/L) from day-0 to month-3, month-6, month-9, month-12

    Time frame: 12 months

  6. Change in renal function

    Percentage of change in Glomerular Filtration Rate estimated by CKD-EPI formula (mL/min/1.73m²) from day-0 to month-3, month-6, month-9, month-12

    Time frame: 12 months

  7. Change in the immunological status of the disease

    Percentage of change in anti-PLA2R1 titer (RU/mL) by ELISA (EUROIMMUN Kit) from day-0 to month-3, month-6, month-9, month-12

    Time frame: 12 months

  8. Appearance of anti-drug antibodies after rituximab treatment

    Serum anti-rituximab antibodies (ng/mL) at month-3, month-6, month-9, month-12

    Time frame: 12 months

  9. Rituximab underdosed patients

    Percentage of patients with serum rituximab (μg/mL) \>2 μg/mL 3 months after the last infusion

    Time frame: 3 months

  10. Serious adverse events

    Occurence of Serious adverse events reported

    Time frame: 84 months

  11. Adaptation of symptomatic treatment

    Number of dose modification of non-immunosuppressive anti-proteinuric treatment during study follow-up

    Time frame: 84 months

  12. Model improvement through machine learning

    serum creatinine and serum albumin levels, weight, anti-PLA2R1 and rituximab level will be combined to report the risk of having undetectable rituximab level after 3 months (in %) at day-0, day-15, day-30, day-45, month-3, month-6

    Time frame: 6 months

  13. Effect of rituximab on immune profiles

    Cytokine levels in pg/mL (IFN-γ, IFN-α, IL-12p70, IL-17A, IL-4, IL-5, IL-10, IL-1, IL-6) at day-0 and month-6

    Time frame: 6 months

07

Study locations

13 of 14 sites recruiting
08

References and documents

Publications

  • Teisseyre M, Destere A, Cremoni M, Zorzi K, Brglez V, Benito S, Bailly L, Fernandez C, Seitz-Polski B. Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial. BMJ Open. 2025 Apr 2;15(4):e093920. doi: 10.1136/bmjopen-2024-093920. PubMed 40180405 ↗

Individual participant data

Plan to share: No — not planed

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Aug 2031, 78 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2024
First posted
Apr 2, 2024
StartActual
Feb 4, 2025
Primary completionEst.
Aug 31, 2031
CompletionEst.
Sep 30, 2031
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06341205
Responsible party
Sponsor
First posted
Apr 2, 2024
Start date
Feb 4, 2025
Primary completion
Aug 31, 2031 (estimated)
Completion
Sep 30, 2031 (estimated)
Last update
Jun 22, 2026

Study contacts

Barbara SEITZ-POLSKI, MD, PhD
Contact
seitz-polski.b@chu-nice.fr
+33492038828
Céline FERNANDEZ
Contact
fernandez.c3@chu-nice.fr
+33492038828

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion